Start Survey
Background information - read me first
Eligibility: Follicular lymphoma grade 1-3a, stage II-IV - previously untreated, current need to treat
This study is recruiting patients. It randomly assigns participants to:
- Lenalidomide with RITUXAN OR
- Rituxan-based chemotherapy
... each followed by Rituxan Maintenance for 2 years. See details on ClinicalTrials.gov
=> Study Arm 1 detail:
Lenalidomide* + Rituxan (See for some background on Lenalidomide)
followed by maintenance Rituxan*
* Oral Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles
if Complete Response after 6 cycles:
then 10-mg on days 2-22 every 28 days for 12 cycles.
if Partial Response after 6 cycles:
continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles
=> Control arm 2: (Regular treatment - detail):
Rituxan combined with your choice of chemotherapy: CHOP, or CVP, or Bendamustine (6 to 8 cycles),
followed by maintenance Rituxan*
* The maintenance Rituxan is the same for each arm. It is given every 8 weeks for 12 cycles
2-Question Patient / Oncologist Survey
capturing no identifying information